NCT06932315View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 23, 2025

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions

Skeletal Muscle Relaxation

Interventions

DRUG

HRS-9190 for Injection

Subject will receive the HRS-9190 injection at different dose levels.

Trial Locations (1)

410013

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06932315 - A Study to Evaluate the Safety, Tolerability and Dose-Response Relationship of HRS-9190 in Healthy Subjects | Biotech Hunter | Biotech Hunter